We studied whether laboratory confirmation of heparin-induced thrombocytopenia (HIT) Thrombocytopenia associated with heparin occurs in a moderate form within a few days of the onset of treatment and spontaneously reverses under continued therapy. If thrombocytopenia occurs 5 to 15 days after the onset of heparin therapy, heparin-induced thrombocytopenia (HIT) is most severe; the platelet count drops to less than 100 ·10 3 /µL (100 ·10 9 /L) or decreases by more than 50% of the pretreatment value, thromboembolism occurs, and the platelet count normalizes only after withdrawal of heparin.
A b s t r a c t

We studied whether laboratory confirmation of heparin-induced thrombocytopenia (HIT) can be improved after antigen clearance by determining free antibody and combining the results of an antigenic and a biologic assay. Blood samples taken over 40 days in 14 patients with HIT with thromboembolism underwent fluorescence-linked immunofiltration and the carbon 14-serotonin release assays.
Of the 14 patients, 11 showed positive results in both assays at day 1 after stopping heparin. The 3 patients with negative results seroconverted in one or both assays during the subsequent 7 days. Combining the positive results of the assays increased the sensitivity from 85% at day 1 to 100% at day 7 
. Assay results became negative in all patients within 40 days. The platelet count normalized between days 2 and 9 after withdrawal of heparin. It is assumed that the free antibody can be detected after withdrawal of heparin and after clearance of the platelet factor 4-heparin complex in patients with HIT.
Thrombocytopenia associated with heparin occurs in a moderate form within a few days of the onset of treatment and spontaneously reverses under continued therapy. If thrombocytopenia occurs 5 to 15 days after the onset of heparin therapy, heparin-induced thrombocytopenia (HIT) is most severe; the platelet count drops to less than 100 ·10 3 /µL (100 ·10 9 /L) or decreases by more than 50% of the pretreatment value, thromboembolism occurs, and the platelet count normalizes only after withdrawal of heparin. 1, 2 The diagnosis of HIT may be difficult on the basis of clinical symptoms alone, especially in patients with other diseases that may induce thrombocytopenia. Laboratory confirmation of HIT therefore is required using biologic or antigen assays. Biologic assays include the carbon 14-serotonin release assay ( 14 C-SRA), 3 the heparin-induced platelet activation assay, 4 and the flow cytometric assay. 5 Antigen assays determine the platelet factor 4 (PF4)-heparin complex by enzymelinked immunosorbent assay, 6 heparin-induced IgG by biotinlabeled PF4, 7 and fluorescent-labeled heparin. 8, 9 The sensitivity of all assays ranges from 80% to 98%. Antigenic and biologic assays have been compared in several studies to define the sensitivity and specificity. [10] [11] [12] [13] [14] [15] [16] Combination of the results of two assays to enhance the laboratory confirmation of HIT has been suggested. 14 An improvement of the sensitivity from 56% to 85% by using a combination of assays has been reported in HIT without thrombosis 17 but has not been studied in HIT with thromboembolism.
HIT may be understood as an immune-complex disease with development of antibodies within 8 to 10 days of starting heparin treatment. The synthesized antibodies result in formation of antigen-antibody complexes, which facilitate removal of the antigen by the reticuloendothelial system. Free antibody can be detected after clearance of the immune complexes. 18 Based on these considerations, we hypothesized that in patients with HIT with negative test results at day 1 of blood sampling, the antibody may appear in the first few days after disappearance of the antigen. The time course of PF4-heparin antibodies during 50 days has been reported in 1 case of HIT, 19 and another patient was monitored for 2 weeks using the 14 C-SRA. 20 In the present article, we report on the time course of biologic and antigen findings in patients with HIT using the fluorescence-linked immunofiltration assay (FLIFA) 9 and the 14 C-SRA. 3 
Materials and Methods
Patients
The diagnosis of HIT was made in 14 patients during heparin treatment, if all of the following criteria were fulfilled: platelet drop to less than 100 ·10 3 /µL (100 ·10 9 /L) or a decrease by more than 50% of the pretreatment value, occurrence of thromboembolism during heparinization, return of the platelet count to the pretreatment value after the end of heparin therapy, and exclusion of other causes of thrombocytopenia. Pseudothrombocytopenia, acute idiopathic thrombocytopenic purpura, immune disease, major hemorrhage, septicemia, consumption coagulopathy, overt tumor disease, and antineoplastic therapy were the main diagnoses considered during the exclusion of other causes. Serial blood samples were obtained from all patients for 40 days, starting immediately after the end of heparin treatment, defined as day 1.
Blood was collected from all patients into plastic tubes containing kaolin and was centrifuged within 30 minutes at 1,800g for 20 minutes at room temperature. Serum was divided into aliquots, shock-frozen in liquid nitrogen, and stored at -80 C. The study was approved by the ethics committee II of the University of Heidelberg, Heidelberg, Germany, and informed consent was obtained from each person.
Fluorescence-Linked Immunofiltration Assay
The heparin-induced IgG antibody was determined by fluorescent-labeled heparin in the presence of PF4 and the patient's serum. The assay was performed under previously reported experimental conditions. 8 
C-Serotonin Release Assay
The biologic effect of the patient's heparin-induced IgG antibody was determined using the 14 C-SRA. The assay was performed as previously reported. 3 In brief, platelets were prepared from healthy subjects by collection of blood into acid-citrate-dextrose solution (1:6, vol/vol). Platelet-rich plasma (PRP) was obtained by centrifugation within 10 minutes at 250g and room temperature for 15 minutes. The platelets were washed with calcium-and albumin-free Tyrode buffer containing 2 U/mL apyrase (Sigma Aldrich, Deisenhofen, Germany) and 2 µg/mL rhirudin (Hoechst Marion Roussel, Bad Soden, Germany), pH 6.2, and resuspended in calcium-and magnesiumcontaining albumin-free Tyrode buffer, pH 7.4. The platelet count was adjusted to 300 ·10 3 /µL (300 ·10 9 /L). The PRP was incubated with 14 C-serotonin (Amersham Pharmacia Biotech GmbH, Freiburg, Germany) for 45 minutes at 37 C (10 µCi 14 C-serotonin/mL of PRP). Two hundred microliters of serum was incubated at 56 C for 30 minutes and was centrifuged at 1,800g for 20 minutes at 25 C. Twenty microliters of the middle layer, 75 µL of the platelet preparation, and 5 µL of the heparin solution (0.1 and 100 U heparin, final concentration, 160 U/mg dry substance, Braun AG, Melsungen, Germany) were incubated for 1 hour and at 25 C under gentle mixing. Fifty microliters of a 27-mmol concentration of EDTA (Sigma Aldrich) was added to terminate the reaction. Samples were centrifuged within 10 minutes at 1,800g and room temperature for 20 minutes, and the radioactivity of 50 µL of the supernatant was measured in a scintillation counter (Beckman Instrument GmbH, Munich, Germany). The maximum release of 14 C-serotonin from platelets was obtained after lysis of platelets with 25 µL of Triton X-100 (Sigma Aldrich). A positive result was defined as radioactivity above the 2-fold SD of the negative control. 14 The same positive and negative controls were run in all experiments. © American Society of Clinical Pathologists Results ❚Table 1❚ shows demographic data for the patients, the time course of the platelet count, and the anticoagulant treatment after stopping heparin treatment.
The flow sheets for FLIFA ❚Figure 1❚ and the 14 C-SRA ❚Figure 2❚ show a sensitivity of 80% for both assays at day 1. Three of 11 patients had negative FLIFA results, and their results became positive at days 3 and 7. One of the 11 patients had a positive result for the SRA at day 1. Three of 11 patients had negative 14 C-SRA results at day 1. Results for 2 of the patients became positive 7 days after stopping heparin treatment, whereas the other patient had a positive FLIFA result at day 1. Two of 14 patients had negative results for both assays at day 1, and their results became positive until day 7 in 1 assay each. HIT type II developed in 1 patient each after therapy with unfractionated heparin or low-molecular-weight heparin. By combining the positive results of the two assays, the sensitivity was 85% at day 1 and 100% at day 7. The result was not dependent on which assay was performed first on day 1.
The data for 17 patients without HIT were analyzed to calculate the specificity of the combined assay. The specificity was 88% at day 1, 94% at day 8, and 100% at day 11. Thus, the specificity of the combined assays also increased by repeated analysis.
The FLIFA and the 14 C-SRA were followed up in all patients until results became negative. All patients had negative HIT-IgG antigen and biologic assay results 40 days after stopping heparin treatment. ❚Figure 3❚ shows the ❚Figure 1❚ Flow sheet for the diagnosis of heparin-induced thrombocytopenia (HIT), starting with the antigenic fluorescence-linked immunofiltration assay (FLIFA) at day 1, and follow-up of patients with negative results but for whom there was high clinical suspicion of HIT using the carbon 14-serotonin release assay (SRA) and FLIFA.
❚Figure 2❚ Flow sheet for the diagnosis of heparin-induced thrombocytopenia (HIT), starting with the carbon 14-serotonin release assay (SRA) at day 1, and follow-up of patients with negative results but for whom there was high clinical suspicion of HIT using fluorescence-linked immunofiltration assay (FLIFA) and SRA.
different time courses of the platelet count, the FLIFA, and the 14 C-SRA after stopping heparin treatment. Figure 3A shows the results for 1 patient who had the highest HIT-IgG antibody antigen and activity levels at the time of the platelet nadir. The platelet count normalized within 6 days, and results of the antigen and biologic assays normalized at the same rate, 10 days. Figure 3B shows the results for another patient in whom both assays were positive at the time of the platelet nadir. The IgG antibody concentration in this patient increased during 12 days, while the platelet count and biologic assay result normalized. Figure 3C shows results for a patient in whom heparin-induced IgG antibody appeared at day 7 while the patient was still thrombocytopenic but who had negative 14 C-SRA results during the observation period. Figure 3D shows the results for a patient in the reverse situation, with negative IgG antibody but a positive 14 C-SRA result at day 6. The time courses of the assays in Figure 3 indicate that laboratory confirmation of HIT was still possible for all 4 patients, even several days after stopping heparin treatment and after normalization of the platelet count. The time courses for the platelet counts and results for the two assays for the other 10 patients followed 1 of the 3 patterns presented. The nadir of the platelet count was 76 ·10 3 /µL (76 · 10 9 /L) at day 1, and the count normalized to 266 ·10 3 /µL (266 · 10 9 /L) for all patients within 9 days of stopping heparin therapy (Table 1) .
Combining the positive results in the two assays increased the sensitivity of the laboratory confirmation of HIT to 100% for patients over 7 days. Results of both assays then became negative during a period of 40 days. The cumulative incidence of positive antigenic and biologic assay results and of the combination of assay results over 40 days is shown in ❚Figure 4❚. The cumulative incidence of normalization of the platelet count in patients after stopping heparin treatment is plotted together with the incidence of positive combined assays in ❚Figure 5❚. At day 10, the platelet count had normalized in all patients after stopping heparin therapy. At day 7, all patients showed a positive combined result (ie, the result of 1 of the 2 assays was positive).
Discussion
The present study confirmed reports that antigenic and biologic assays for laboratory confirmation of HIT with thrombosis are positive for only about 80% of patients. After withdrawal of heparin, however, and by repeated testing for heparin-induced antibodies up to day 7, combining the results of antigenic and biologic assays increased sensitivity to 100%. Studies to combine the PF4/heparin enzyme-linked immunosorbent assay with the heparin-induced platelet activation assay or with the platelet aggregation assay have been conducted only in HIT without thrombosis. 17 We decided to choose sensitive and specific biologic and antigenic assays for our study, despite the fact that these assays may be adopted only in a limited number of laboratories. The time courses of these assays in our patients with HIT with thrombosis demonstrate that a positive result in one assay indeed confirms the laboratory diagnosis of HIT. Positive results in 1 of 2 assays can be combined if the assays used have high specificity. The assays used in the present study both have a specificity higher than 95%. 3, 8 At present, clinical HIT with thrombocytopenia and thromboembolic complications will not be confirmed by laboratory testing in 10% to 20% of patients. An inappropriate decision to continue heparin treatment in these patients might be made. It remains difficult to diagnose HIT based on clinical findings because the patients at greatest risk for HIT are severely ill with many other possible causes for thrombocytopenia or microvascular or macrovascular thrombotic events. Since an ideal assay for HIT has not been established, a different strategy for diagnosis is necessary.
An increase in free antibodies has been described in immune complex diseases. 18 On the first exposure to the antigen, the host develops the antibody response after a week or 10 days. The synthesized antibodies result in formation of antigen-antibody complexes, which facilitate removal of the antigen in general by cells in the reticuloendothelial system. Antigen disappears from the circulation in 3 phases: the first represents equilibration of the antigen between the intravascular and extravascular compartments; the second is produced by catabolism of the antigen; the third involves the immune clearance of the antigen by newly formed specific antibodies. 21 As more antibody is synthesized, the lattice structure of the immune complexes increases, until the complexes reach a critical size and then are removed rapidly from the circulation by the reticuloendothelial system. The complexes are cleared within 7 days, and free antibody can be detected. 18, 21 In the present study, this mechanism was believed to be of importance in patients with HIT. The results show that all negative results of the antigenic tests in patients with HIT became positive during the following 7 days, and most were also positive in the biologic 14 C-SRA after clearance of the antigen. The cumulative frequency of positive antigen and biologic assay results increased over 7 days, while the platelet count normalized during this period, indicating termination of the immunologic process of the disease. This complies with the described mechanisms for immune complex diseases, in which the pathogenic process ceases after clearance of the antigen-antibody complexes, and free antigen can be detected. Thereafter the antigen is eliminated within a period of 4 to 6 weeks, which has been described in 2 case reports. 19, 20 The reason for the more rapid decrease in the normalization of the heparin-induced IgG antibody in these patients, when compared with the decrease in IgG antibodies in other immunologic diseases, remains unclear.
Our findings also agree with the observation that patients who were tested only on the day when heparin treatment was stopped should be considered still to have a substantial risk of developing thrombotic complications. 20 So far, in contrast with the platelet count, the antigen and biologic assays for laboratory confirmation of HIT have not been followed up in a larger number of patients. Thus, follow-up of 1 week after onset of the disease and the combination of two sensitive assays may improve the laboratory confirmation of HIT. Follow-up in our patients with HIT revealed 4 patterns for heparin-induced antibodies. Pattern 1 is characterized by positive antigenic test results at the nadir of the platelet count and similar time courses for the normalization of the antigen and biologic assay results, while pattern 2 shows dissimilar time curves for the assay results. Patterns 3 and 4 are positive in only 1 of the 2 assays. There are many possible reasons for the differences between the antigenic and biologic assay results, including the polyclonal structure of the IgG antibody and the possibility of interleukin-8 or neutrophil-activating peptide as antigens. 22 The platelet count normalized in all patients within 10 days, indicating that the disappearance of the PF4-heparin complex is an important factor in the subsidence of the disease, and not the disappearance of the antibody. Thus, laboratory confirmation of HIT also may be possible in a large number of patients after normalization of the platelet count as shown in Figure 5 . It should be borne in mind, however, that the present study included only patients with clinically confirmed HIT. Therefore, a normal platelet count does not exclude circulating antibodies with reactivity toward heparins, indicating an increased risk of these patients for development of thromboembolism over a long period.
Serial measurements of sensitive heparin-induced IgG antibody and 14 C-SRAs confirmed the diagnosis in all patients with HIT. After elimination of the antigen, platelets and free antibody increase over 7 to 10 days as the antigenantibody complex is interrupted. Further studies are necessary to show whether these findings can be transferred to combinations of other antigenic and biologic assays for laboratory confirmation of HIT.
